Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients

Clinical Pharmacology and Therapeutics
C WyenA Jetter

Abstract

This study aimed to quantify the inhibition of cytochrome P450 (CYP3A), CYP2D6, and P-glycoprotein in human immunodeficiency virus (HIV)-infected patients receiving an antiretroviral therapy (ART) containing ritonavir boosted lopinavir, and to identify factors influencing ritonavir and lopinavir pharmacokinetics. We measured activities of CYP3A, CYP2D6, and P-glycoprotein in 28 patients before and during ART using a cocktail phenotyping approach. Activities, demographics, and genetic polymorphisms in CYP3A, CYP2D6, and P-glycoprotein were tested as covariates. Oral midazolam clearance (overall CYP3A activity) decreased to 0.19-fold (90% confidence interval (CI), 0.15-0.23), hepatic midazolam clearance and intestinal midazolam availability changed to 0.24-fold (0.20-0.29) and 1.12-fold (1.00-1.26), respectively. In CYP2D6 extensive metabolizers, the plasma ratio AUC(dextromethorphan)/AUC(dextrorphan) increased to 2.92-fold (2.31-3.69). Digoxin area under the curve (AUC)(0-12) (P-glycoprotein activity) increased to 1.81-fold (1.56-2.09). Covariates had no major influence on lopinavir and ritonavir pharmacokinetics. In conclusion, CYP3A, CYP2D6, and P-glycoprotein are profoundly inhibited in patients receiving ritonavir boosted lo...Continue Reading

References

Apr 1, 1996·Journal of Clinical Psychopharmacology·M J Byerly, C L DeVane
Sep 5, 1998·Clinical Pharmacology and Therapeutics·J C GorskiS D Hall
Nov 13, 1998·Clinical Pharmacokinetics·A HsuR J Bertz
Jul 20, 1999·The Journal of Clinical Investigation·B GreinerH K Kroemer
Jun 10, 2000·British Journal of Clinical Pharmacology·M SomerM Scheinin
Aug 17, 2000·Clinical Pharmacology and Therapeutics·L LabbéJ Turgeon
Feb 5, 2002·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·V A EaglingD J Back
Apr 30, 2002·The Annals of Pharmacotherapy·Deborah V KellyM Ian Bowmer
Jun 28, 2002·The New England Journal of Medicine·Sharon WalmsleyUNKNOWN M98-863 Study Team
Sep 24, 2002·The Annals of Pharmacotherapy·Tony Antoniou, Alice Lin-In Tseng
Nov 1, 2002·Clinical Neuropharmacology·Francisco JoverJaime Merino
Jan 25, 2003·Clinical Pharmacology and Therapeutics·Céline VerstuyftLaurent Becquemont
Apr 17, 2003·European Journal of Clinical Pharmacology·Céline VerstuyftLaurent Becquemont
Nov 6, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David W HaasRichard B Kim
Jul 2, 2004·Clinical Pharmacology and Therapeutics·Reinhard DingWalter E Haefeli
Sep 18, 2004·British Journal of Clinical Pharmacology·Margit FröhlichWalter E Haefeli
Nov 24, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ursula LutzWerner K Lutz
Jan 7, 2005·AIDS Patient Care and STDs·C TortiUNKNOWN RADAR Study Group of the Master Cohort
Jan 20, 2005·European Journal of Clinical Pharmacology·Jacques FellayChin B Eap
Apr 12, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Silvana BorgesJ Christopher Gorski
May 25, 2005·Fundamental & Clinical Pharmacology·Andrew OwenDavid J Back
Jul 26, 2005·Pharmacogenetics and Genomics·Sara ColomboUNKNOWN Swiss HIV Cohort Study
Sep 20, 2005·Annals of Clinical Biochemistry·Salim FredericksDavid W Holt
Dec 13, 2005·Clinical Pharmacology and Therapeutics·Rob E AarnoutseDavid M Burger
Jun 23, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Peter L AndersonCourtney V Fletcher
Aug 8, 2006·Clinical Pharmacology and Therapeutics·Manon J van der LeeDavid M Burger
Feb 3, 2007·European Journal of Clinical Pharmacology·D FrankU Fuhr

❮ Previous
Next ❯

Citations

Aug 28, 2009·The Journal of Antimicrobial Chemotherapy·Peter L AndersonSamantha MaWhinney
Feb 10, 2012·The Journal of Antimicrobial Chemotherapy·Pauline Byakika-KibwikaConcepta Merry
Apr 7, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mohammed LamordeConcepta Merry
May 27, 2014·Expert Opinion on Drug Discovery·Bo FengLarry Tremaine
Mar 22, 2013·Expert Opinion on Drug Metabolism & Toxicology·John C SchoenPeter L Anderson
Aug 21, 2012·Basic & Clinical Pharmacology & Toxicology·Virginie AncrenazJules Desmeules
May 19, 2010·Transplant International : Official Journal of the European Society for Organ Transplantation·Johann MorelleNada Kanaan
Jun 24, 2011·Journal of Pharmaceutical Sciences·Latoya GriffinKim L R Brouwer
Dec 23, 2015·Pharmaceutical Statistics·Thu Thuy NguyenNatacha Lenuzza
Dec 4, 2014·European Journal of Drug Metabolism and Pharmacokinetics·Natacha LenuzzaHenri Bénech
Jun 18, 2014·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Yukari UmeyamaTeruaki Okuda
Jan 1, 2010·Clinical Pharmacology and Therapeutics·A A MathiasB P Kearney
May 22, 2009·Clinical Pharmacology and Therapeutics·D Tomalik-ScharteU Fuhr
Jun 14, 2016·International Journal of Pharmaceutics·Ching Kim TyeMichael J Hageman
Sep 30, 2015·The American Journal of Tropical Medicine and Hygiene·Siwalee RattanapunyaKesara Na-Bangchang
Jun 30, 2009·European Journal of Clinical Pharmacology·Natascia CortiChristiane Pauli-Magnus
Apr 13, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Rebecca BegleyJoseph M Custodio
Nov 20, 2018·Journal of Clinical Pharmacology·Mario R SampsonIslam R Younis
Sep 18, 2008·European Journal of Clinical Pharmacology·Andrea GaedigkUwe Fuhr
Feb 3, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Tamsin A KnoxDavid J Greenblatt
Mar 11, 2010·Clinical Pharmacokinetics·Joseph D MaAnne N Nafziger
Aug 11, 2010·European Journal of Clinical Pharmacology·Tuija H NieminenKlaus T Olkkola
Aug 24, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose R Castillo-MancillaPeter L Anderson
Apr 12, 2019·Journal of Clinical Pharmacology·Islam R YounisChandra G Sahajwalla
May 22, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Francesca PattiStefano Bonora
Apr 6, 2019·Expert Opinion on Drug Metabolism & Toxicology·Yuqing GongSantosh Kumar
Sep 20, 2008·BMC Bioinformatics·Taewon LeeRobert R Delongchamp
Oct 26, 2013·Clinical Pharmacokinetics·Tony K L KiangMary H H Ensom
Apr 19, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Vanja Petrovic, Micheline Piquette-Miller
Oct 7, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Brooke M VandenBrinkJan L Wahlstrom
Sep 27, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Evan D Kharasch, Kristi Stubbert
Apr 30, 2015·British Journal of Clinical Pharmacology·David J Greenblatt, Jerold S Harmatz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.